Cradle
Amsterdam generative-AI company whose protein engineering platform applies large-language-model techniques to generate amino-acid sequence variants optimised for activity, binding and stability, co-optimising several properties per design round and fine-tuning on each customer's own wet-lab data for antibodies, enzymes, peptides and vaccine antigens.
Headquarters
Amsterdam, Netherlands
Year Founded
2021
Founders
Stef van Grieken (CEO), Jelle Prins, Elise de Reus, Eli Bixby, Harmen van Rossum
Country
Netherlands
Financial Information
Funding Stage
Series B
Recent Funding
$100M+
Funding By
IVP, Index Ventures, Kindred Capital
Core Technology
Generative AI protein design using LLM-derived models fine-tuned on customer wet-lab data
Product Type
AI Platform
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: N/A
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Not disclosed
Partnerships
Pharma Collaborations
Pharmaceutical and biotech customers (undisclosed)
Academic / Hospital Tie-ups
Not disclosed
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Multi-property co-optimisation in a single design round, with a data flywheel from customer wet labs